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ABSTRACT
Objectives Home is considered the preferred
place of death for many, but patients with
haematological malignancies (leukaemias,
lymphomas and myeloma) die in hospital more
often than those with other cancers and the
reasons for this are not wholly understood. We
examined preferred and actual place of death
among people with these diseases.
Methods The study is embedded within an
established population-based cohort of patients
with haematological malignancies. All patients
diagnosed at two of the largest hospitals in the
study area between May 2005 and April 2008
with acute myeloid leukaemia, diffuse large B-
cell lymphoma or myeloma, who died before
May 2010 were included. Data were obtained
from medical records and routine linkage to
national death records.
Results 323 deceased patients were included. A
total of 142 (44%) had discussed their preferred
place of death; 45.8% wanted to die at home,
28.2% in hospital, 16.9% in a hospice, 5.6% in
a nursing home and 3.5% were undecided;
63.4% of these died in their preferred place.
Compared to patients with evidence of a
discussion, those without were twice as likely to
have died within a month of diagnosis (14.8% vs
29.8%). Overall, 240 patients died in hospital;
those without a discussion were significantly
more likely to die in hospital than those who had
(p≤0.0001). Of those dying in hospital, 90%
and 75.8% received haematology clinical input
in the 30 and 7 days before death, respectively,
and 40.8% died in haematology areas.
Conclusions Many patients discussed their
preferred place of death, but a substantial
proportion did not and hospital deaths were
common in this latter group. There is scope to
improve practice, particularly among those dying
soon after diagnosis. We found evidence that some
people opted to die in hospital; the extent to which
this compares with other cancers is of interest.
INTRODUCTION
When asked, most people say that given a
choice, home is the place they would
prefer to die.1–6 While this preference is
increasingly being met in the UK, a large
proportion of people still do not die in
their preferred place;7 8 and this is par-
ticularly apparent among patients with
haematological malignancies, in the UK
and elsewhere.8–14 Haematological malig-
nancies are complex cancers, broadly
categorised as leukaemias, lymphomas
and myeloma, but actually comprising
numerous different subtypes. These dis-
eases can be indolent or aggressive and
may be incurable at diagnosis, potentially
curable or manageable with medication
in a way similar to chronic rather than
malignant conditions. Regardless of these
differences, around two-thirds of people
with haematological malignancies die in
hospital, across all subtypes.10
Being able to die in one’s preferred
place is recognised as a ‘quality marker’
by the UK National Health Service.15 16
Consequently, the large proportion of
hospital deaths among patients with
haematological cancers, which has been
described as a ‘consistent inequality’,11
may be considered to imply that people
with these diseases have poorer
end-of-life experiences than others, as
they do not die in their place of choice.
There is now a growing body of evi-
dence about the care of patients with
haematological malignancies in the final
weeks and days of their life, and this is in
many respects far from reassuring. In
comparison to patients with other dis-
eases, for example, these people are not
only reportedly more likely to die in hos-
pital,9 10 but they are also more likely to
receive aggressive or intensive care at this
time,17–20 and less likely to receive input
from specialist palliative care or hospice
services.21 Qualitative studies, particularly
in Australia, describe patients often dying
in acute settings with escalating technol-
ogy, invasive treatments and limited
access to their families.22 23
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There are still many information gaps, however,
with a distinct lack of research exploring why path-
ways and care patterns among patients with haemato-
logical cancers tend to differ from those with other
diseases. One important area that has not previously
been explored is the care preferences of haematology
patients at the end of life and whether these are met;
and this study was initiated to examine this topic.
Specific aims were to examine the frequency of discus-
sions about preferred place of death, stated prefer-
ences and congruence between preferred and actual
place of death. The influence of patient characteristics,
disease subtype, time from diagnosis to death and the
clinical area of care are also explored.
METHODS
This UK study is embedded within an established
population-based patient-cohort of haematological
malignancies—the Haematological Malignancy
Research Network (HMRN) (http://www.HMRN.org).
Initiated in 2004, HMRN operates with Section 251
support under the National Health Service (NHS) Act
2006 and full details of its structure, data collection
methods and ethical approvals have been previously
described.24 25 Briefly, HMRN covers a population of
nearly four million, which is sociodemographically rep-
resentative of the UK as a whole; all diagnoses are
made and coded by clinical specialists at a single inte-
grated haematopathology laboratory, and clinical prac-
tice across the region adheres to national
guidelines.24 25 With respect to follow-up, all patients
have full treatment, response and outcome data col-
lected to clinical trial standards, and death notification
information (which includes place of death) is routinely
obtained from the national Medical Research
Information Service (MRIS).
The research reported here is part of an ongoing
programme of work examining palliative and
end-of-life issues in haematological cancers, and is
based at two large teaching hospitals (York and Hull)
where around 30% of all HMRN patients are treated.
This research, which includes patients diagnosed with
acute myeloid leukaemia (AML), diffuse large B-cell
lymphoma (DLBCL) and myeloma between 1 May
2005 and 30 April 2008 who died before 30 April
2010, has additional independent ethical approvals
and the methods employed are fully described else-
where.26 In brief, core HMRN data were supplemen-
ted using a calendar approach to record the patients’
whereabouts on a day-by day basis (eg, home, hos-
pital, hospice), as well as their care-related activities,
such as clinical area/specialty providing care within
the hospital.26 Information was also collected about
place of death discussions and preferences, including
changes in preferences over time, if these occurred.
A number of different sources were scrutinised to
obtain the required data. Both the hospital medical
records and any community palliative care records
were searched, and we targeted official forms specific-
ally designed to document preferences, as well as
information written in free text or contained in cor-
respondence between care providers. Place of death
was grouped into four categories, including ‘home’,
‘hospital’, ‘hospice’ or ‘nursing home’. The preference
closest to death was used to determine congruence
between preferred and actual place of death. Data
analyses were carried out using standard statistical
methods with SAS software V.9.3,27 and Fisher’s exact
test was used to test for statistical significance.
RESULTS
A total of 323 patients (178 men and 145 women)
with AML (n=107), DLBCL (n=102) or myeloma
(n=114) were diagnosed at the two hospitals between
1 May 2005 and 30 April 2008 and died before 30
April 2010—a minimum of 2 years and a maximum
of 5 years follow-up (table 1). As expected, most
patients (82.1%) were aged 60 years and above at
diagnosis; over two-thirds died within a year of diag-
nosis and almost a quarter (23.2%) within a month of
diagnosis. The vast majority of patients (n=240,
74.3%) died in hospital, followed by home (n=49,
15.2%), hospice (n=18, 5.6%) and nursing home
(n=16, 4.9%).
Evidence of a discussion about preferred place of
death was found for 142 (44%) patients (table 1) and
this proportion varied little by diagnosis. Compared
to patients where evidence of a discussion was found,
those with no documented discussion about preferred
place of death were twice as likely to have died within
a month of diagnosis (14.8% vs 29.8%). This differ-
ence was evident across all cancer groups—AML
(20.4% vs 34.4%), DLBCL (20.9% vs 39.0%) and
myeloma (4.0% vs 17.2%). The proportion of people
dying in hospital was higher among those where no
discussion about preferred place of death had taken
place (84%) than among those where it had (62%)
(p≤0.0001).
Of the 142 patients with evidence of a discussion
about preferred place of death (table 2), the most
common preference was home (n=65, 45.8%), fol-
lowed by hospital (n=40, 28.2%), hospice (n=24,
16.9%) and nursing home (n=8, 5.6%). Five patients
(3.5%) discussed place of death, but were undecided
about this at the time of the discussion. Overall, 90 of
the 142 patients (63.4%) with evidence of a discus-
sion about place of death died in their preferred
place. While all patients who expressed a preference
to die in hospital did so, only around half of the
patients who stated a preference to die at home, in a
hospice or a nursing home died in their preferred
place, and no variations by diagnostic group were
observed. Patients being cared for by the haematology
team at the time of their death were significantly
more likely to have opted to die in hospital than
patients dying in other hospital settings (p=0.0067).
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There was some variation in the clinical specialties
providing care at the time of death, with less than half
(n=98, 40.8%) of the 240 hospital deaths occurring
in haemato-oncology settings (table 3). Indeed, 52
patients (21.7%) died in elderly/general medical areas,
and others died in intensive care/high dependency
units (ICU/HDU) (n=26, 10.8%), renal medicine
(n=12, 5%) or accident and emergency (A&E)
departments (n=9, 3.7%). A relatively small propor-
tion (n=18, 7.5%) died in hospital palliative care
areas. With respect to variation by disease subtype,
patients with AML were more likely than those with
DLBCL or myeloma to die on haemato-oncology
wards, the proportions being 50.0%, 23.5% and
27.6%, respectively (p=0.0002). Conversely, those
with DLBCL or myeloma were more likely than those
with AML to die in elderly/general medical settings.
As expected, patients with myeloma were the most
likely to die in renal areas, and those with AML and
DLBCL on ICU/HDU. Similar proportions died in
palliative care settings across diagnostic groups.
With respect to prior discussion about place of
death among patients dying in hospital (table 3), this
was most likely to have occurred when patients died
within palliative care areas (72.2%), followed by
haemato-oncology (41.8%) and elderly/general medi-
cine (38.5%). As might be expected, those dying in
ITU/HDU or A&E were least likely to have had a dis-
cussion about their preferred place of death (3.8%
and 11.1%, respectively).
Despite deaths occurring in a number of different
hospital settings, 90% of patients received haematol-
ogy input during the last month of life, including all
patients dying on renal wards and in A&E, 84.6%
of those in ITU/HDU, 80.8% in elderly/medicine
and 72.2% in palliative care areas (table 3). During
the final week of life, this changed to 75.8% receiv-
ing haematology input overall, and although the
proportion remained constant in ITU/HDU, it
decreased to 66% in renal and A&E areas, 53.8%
in elderly/medical and 22.2% in palliative care
settings.
Table 1 Demographic and clinical characteristics of the 323 patients diagnosed with AML, DLBCL or myeloma at the two HMRN study
hospitals between May 2005 and April 2008 who died before May 2010
All deaths (n=323)
All diagnoses (N=323) AML (N=107) DLBCL (N=102) Myeloma (N=114)
Place of death
discussion
Place of death
discussion
Place of death
discussion
Place of death
discussion
Yes
N (%)
No*
N (%)
Yes
N (%)
No*
N (%)
Yes
N (%)
No*
N (%)
Yes
N (%)
No*
N (%)
Total 323 (100) 142 (100) 181 (100) 49 (100) 58 (100) 43 (100) 59 (100) 50 (100) 64 (100)
Sex
Male 178 (55.1) 76 (53.5) 102 (56.4) 27 (55.1) 34 (58.6) 17 (39.5) 29 (49.2) 32 (64.0) 39 (60.9)
Female 145 (44.9) 66 (46.5) 79 (43.6) 22 (44.9) 24 (41.4) 26 (60.5) 30 (50.8) 18 (36.0) 25 (39.1)
Age at diagnosis
≤60 58 (17.9) 25 (17.6) 33 (18.2) 9 (18.4) 16 (27.6) 9 (20.9) 9 (15.2) 7 (14.0) 8 (12.5)
61–74 122 (37.8) 50 (35.2) 72 (39.8) 16 (32.6) 23 (39.7) 13 (30.2) 26 (44.1) 21 (42.0) 23 (35.9)
75+ 143 (44.3) 67 (47.2) 76 (42.0) 24 (49.0) 19 (32.8) 21 (48.8) 24 (40.7) 22 (44.0) 33 (51.6)
Mean (SD) 71.5 (12.8) 71.9 (12.6) 71.2 (13.0) 71.7 (13.9) 66.5 (14.4) 71.3 (13.5) 73.0 (13.3) 72.5 (10.4) 73.9 (10.1)
Age at death
≤60 53 (16.4) 23 (16.2) 30 (16.6) 8 (16.3) 16 (27.6) 8 (18.6) 8 (13.5) 7 (14.0) 6 (9.4)
61–74 117 (36.2) 49 (34.5) 68 (37.6) 16 (32.7) 22 (37.9) 14 (32.6) 25 (42.4) 19 (14.0) 21 (32.8)
75+ 153 (47.4) 70 (49.3) 83 (45.8) 25 (51.0) 20 (34.5) 21 (48.8) 26 (44.1) 24 (48.0) 37 (57.8)
Mean (SD) 72.4 (12.7) 72.8 (12.3) 72.0 (13.0) 72.2 (13.8) 67.2 (14.2) 72.2 (13.3) 73.6 (13.4) 73.9 (10.0) 75.0 (10.0)
Time from diagnosis to death (months)
≤1 75 (23.2) 21 (14.8) 54 (29.8) 10 (20.4) 20 (34.4) 9 (20.9) 23 (39.0) 2 (4.0) 11 (17.2)
1–6 83 (25.7) 35 (24.7) 48 (26.5) 19 (38.8) 16 (27.6) 9 (20.9) 18 (30.5) 7 (14.0) 14 (21.9)
6–12 62 (19.2) 33 (23.2) 29 (16.1) 13 (26.5) 11 (19.0) 11 (25.6) 5 (8.5) 9 (18.0) 13 (20.3)
12+ 103 (31.9) 53 (37.3) 50 (27.6) 7 (14.3) 11 (19.0) 14 (32.6) 13 (22.0) 32 (64.0) 26 (40.6)
Mean (SD) 10.6 (12.0) 11.8 (11.6) 9.7 (12.2) 5.9 (6.1) 7.4 (9.8) 10.6 (11.2) 7.7 (12.1) 18.6 (12.6) 13.5 (13.5)
Place of death
Hospital 240 (74.3) 88 (62.0) 152 (84.0) 28 (57.1) 53 (91.4) 28 (65.1) 50 (84.7) 32 (64.0) 49 (76.6)
Home 49 (15.2) 34 (23.9) 15 (8.3) 13 (26.5) 3 (5.2) 10 (23.3) 5 (8.5) 11 (22.0) 7 (10.9)
Hospice 18 (5.6) 13 (9.2) 5 (2.8) 6 (12.3) 1 (1.7) 4 (9.3) 2 (3.4) 3 (6.0) 2 (3.1)
Nursing home 16 (4.9) 7 (4.9) 9 (4.9) 2 (4.1) 1 (1.7) 1 (2.3) 2 (3.4) 4 (8.0) 6 (9.4)
*No evidence of a discussion about preferred place of death could be found in medical records.
AML, acute myeloid leukaemia; DLBCL, diffuse large B-cell lymphoma; HMRN, Haematological Malignancy Research Network.
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Many patients dying in hospital also received input
from specialties other than their main team at this
time, with 86.7% of patients dying in haemato-
oncology settings, for example, receiving care from
other specialties during the 30 days preceding death,
reducing to 61.2% in the last 7 days. In comparison to
those who died in hospital, 71% of those who died
elsewhere had haematology input in the last month of
life, falling to 19% in the final week.
DISCUSSION
This is the first study to examine preferred and actual
place of death in patients with haematological malig-
nancies. Evidence about this is crucial to ensure that as
many patients as possible receive optimum end-of-life
care and die in the place of their choosing. As
expected, most people died in hospital, and although
many (44%) took part in a discussion about preferred
place of death, over half did not; this was particularly
common among patients dying soon after diagnosis.
Of those with evidence of a discussion, over a quarter
(28.2%) wanted to remain in hospital at the time of
their death, and less than half (45.8%) wanted to be in
their own home. Taking part in a discussion about pre-
ferred place of death significantly impacted on actual
place of death, and a substantial proportion (63.4%) of
people who had had this discussion died in their pre-
ferred place; nonetheless, over a third did not.
There are a number of reasons why hospital deaths are
common among haematology patients and why discus-
sions about place of death might not occur. The first
relates to the complexities associated with these diseases,
their pathways and management. Haematology patients
are often treated aggressively with toxic chemotherapy,
both soon after diagnosis and at subsequent intervals
thereafter if their disease follows a remitting/relapsing
course. This often results in hospitalisation; it may also
lead to rapid deterioration, and sometimes sudden
death.28–31 In this case, the transition from curative or
life-prolonging care to a palliative approach may occur
rapidly, leaving little time for advance care planning and
discussion about preferred place of death.32 Indeed, such
situations may explain to some extent the relatively high
proportion of people, particularly with AML and
DLBCL, who died in intensive care settings, with escal-
ation of treatment and a focus on prolonging life.
Unsurprisingly, we found evidence that discussions about
preferred place of death occurred infrequently in this
setting.
Further complexities in care transitions were noted
due to the unpredictability of treatment response. It
was not uncommon, for example, for sudden deterior-
ation to occur on a background of previously stable
disease or steady decline, a scenario which perhaps
has more in common with the terminal phase of
chronic diseases, such as heart failure, than other
malignancies.33 Such patterns result in care transitions
being regarded as notoriously difficult to identify in
these diseases.12 This may mean advance care plan-
ning is deferred, or does not occur in time for home
death to be considered or organised.
Haematology patients often require supportive care
during their disease, resulting in frequent hospitalisa-
tions. For example, blood product transfusions and
intravenous antibiotics are needed to manage compli-
cations, including bone marrow failure, anaemia,
bleeding and sepsis, and pain may also be a significant
problem.34–36 The situation is complicated by factors
such as the availability of multiple lines of treatment,
even in the later disease stages, which may be given to
manage symptoms rather than with curative or disease
modifying intent.28 29 In this context, chemotherapy
may continue into the terminal phase, again compli-
cating the transitions in care.
Most people in our study who stated a preferred
place of death, but died elsewhere, died in hospital.
Table 2 Discussion about preferred placed of death in patients diagnosed with AML, DLBCL and myeloma at the two HMRN study
hospitals between May 2005 and April 2008 who died before May 2010, and congruence between preferred and actual place of death in
those with a discussion (n=142)
Actual place of death (N %)
Total (N %) Hospital Home Hospice Nursing home
All deaths 323 (100) 240 (74.3) 49 (15.2) 18 (5.6) 16 (5.0)
Discussion about preferred place of death
No 181 (100) 152 (84.0) 15 (8.3) 5 (2.8) 9 (5.0)
Yes 142 (100) 88 (62.0) 34 (23.9) 13 (9.2) 7 (4.9)
Preferred place of death
Hospital 40 (100) 40 (100.0) – – –
Home 65 (100) 31 (47.7) 32 (49.2) – 2 (3.1)
Hospice 24 (100) 11 (45.8) – 13 (54.2) –
Nursing home 8 (100) 3 (37.5) – – 5 (62.5)
Undecided 5 (100) 3 (60.0) 2 (40.0) – –
Shaded area represents the number and proportion of patients who died in their preferred place.
AML, acute myeloid leukaemia; DLBCL, diffuse large B-cell lymphoma; HMRN, Haematological Malignancy Research Network.
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Sometimes, the reasons for this were relatively clear,
including those determined by access to limited
resources (eg, hospice or nursing home beds), equip-
ment (eg, bed, commode, oxygen, hoist) or services
(eg, district nurses, night sitters) if the patient wanted
to return home to die. Sudden deterioration meant
these resources were often needed at short notice, but
were not always available. In common with other
studies,37 social circumstances, carer preferences, or
indeed lack of a carer appeared to prevent some home
discharges. Often, however, we found we could not
determine why preferred place of death had not been
discussed, or preferences met.
Our study showed that some patients opt to remain
in hospital to die. Others also report that hospital
may indeed be considered a ‘safe haven’ and a place
that provides the best possible care, around the clock,
at a time when death is feared and cure is hoped
for.38 39 We found that patients were significantly
more likely to choose to remain in hospital if they
were managed within a haematology area, and this
may be due to the close relationship they (and often
their relatives) have with the team providing their
care.9 12 40 41 This is often established over a number
of years, perhaps developing from a shared under-
standing of the experiences and emotions associated
with an unpredictable disease and frequent hospital
contacts. Patients may also choose to remain in hos-
pital to ensure that their symptoms are effectively
managed during the terminal stages by a team they
know and trust. Alternatively, being at home at this
time may not meet patient or carer expectations,
leading to hospital readmission as the patient becomes
increasingly ill.
We identified a multidisciplinary approach to care
during the last month and week of life, which demon-
strates the complexity of haematological malignancies
at this time. Although many hospital deaths occurred
Table 3 Clinical area at time of death in 240 patients diagnosed with AML, DLBCL or myeloma at the two HMRN study hospitals
between May 2005 and April 2008 who died in hospital before May 2010, and variation by cancer type, discussion about place of death
and specialties contributing to care ≤30 days and ≤7 days before death
Clinical area at time of death
All hospital
deaths
Haemato-
oncology
Elderly/
general
medicine
ICU/
HDU
Palliative
care Renal A&E Other*
Not
Known
N (%) N (%) N (%) N (%) N (%) N (%) N (%) N (%) N
Total 240 (100) 98 (100) 52 (100) 26 (100) 18 (100) 12 (100) 9 (100) 22 (100) 3
Cancer type
AML 81 (33.8) 48 (50.0) 10 (19.2) 11 (42.3) 5 (27.8) – 2 (22.2) 4 (18.2) 1
DLBCL 78 (32.5) 23 (23.5) 22 (42.3) 10 (38.5) 7 (38.9) 1 (8.3) 4 (44.4) 9 (40.9) 2
Myeloma 81 (33.8) 27 (27.6) 20 (38.5) 5 (19.2) 6 (33.3) 11 (91.7) 3 (33.3) 9 (40.9) –
Discussion about place of death
No 152 (63.3) 57 (58.2) 32 (61.5) 25 (96.2) 5 (27.8) 9 (75.0) 8 (88.9) 14 (63.6) 2
Yes 88 (36.7) 41 (41.8) 20 (38.5) 1 (3.8) 13 (72.2) 3 (25.0) 1 (11.1) 8 (36.4) 1
Specialties contributing to care ≤30 days before death†
Haemato-oncology 216 (90.0) 98 (100.0) 42 (80.8) 22 (84.6) 13 (72.2) 12 (100.0) 9 (100.0) 18 (81.8) 2
Elderly/general medicine 133 (55.4) 41 (41.8) 52 (100) 9 (34.6) 7 (38.9) 6 (50.0) 3 (33.3) 15 (68.2) –
ICU/HDU 62 (25.8) 15 (15.3) 10 (19.2) 26 (100) – 4 (33.3) 2 (22.2) 5 (22.7) –
Palliative 82 (34.2) 34 (34.7) 14 (26.9) 3 (11.5) 18 (100) 2 (16.7) 1 (11.1) 9 (40.9) 1
Renal 29 (12.1) 8 (8.2) 4 (7.7) 4 (15.4) – 12 (100) – 1 (4.5) –
A&E 77 (32.1) 19 (19.4) 26 (50.0) 12 (46.2) 2 (11.1) 1 (8.3) 9 (100) 8 (36.4) –
Other 131 (54.6) 53 (54.1) 22 (42.3) 16 (61.5) 9 (50.0) 5 (41.7) 4 (44.4) 22 (100) –
Specialties contributing to care ≤7 days before death†
Haemato-oncology 182 (75.8) 98 (100.0) 28 (53.8) 22 (84.6) 4 (22.2) 8 (66.7) 6 (66.6) 16 (72.7) –
Elderly/general medicine 85 (35.4) 18 (18.4) 52 (100) 5 (19.2) – 3 (25.0) – 7 (31.8) –
ICU/HDU 52 (21.7) 9 (9.2) 8 (15.4) 26 (100) – 3 (25.0) 2 (22.2) 4 (18.2) –
Palliative 69 (28.8) 25 (25.5) 13 (25.0) 3 (11.5) 18 (100) 1 (8.3) 1 (11.1) 7 (31.8) 1
Renal 27 (11.3) 7 (7.1) 4 (7.7) 3 (11.5) – 12 (100) – 1 (4.5) –
A&E 38 (15.8) 7 (7.1) 14 (26.9) 6 (23.1) – – 9 (100) 2 (9.1) –
Other 77 (32.1) 26 (26.5) 8 (15.4) 9 (34.6) 7 (38.9) 3 (25.0) 2 (22.2) 22 (100) –
*Other includes: coronary care unit/Cardiology (n=7), general surgery (n=7), infectious disease (n=2), respiratory (n=2), gastroenterology (n=1),
orthopaedic (n=1), rehabilitation (n=1), plastic surgery (n=1).
†Includes input provided by any clinical specialty, which is additional to that given by the main provider shown in the column heading.
A&E, accident and emergency department; AML, acute myeloid leukaemia; DLBCL, diffuse large B-cell lymphoma HMRN, Haematological Malignancy
Research Network; ICU/HDU, intensive care unit/high dependency unit.
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outside haematology areas, 90% of patients received
haematology input in the 30 days preceding death,
reflecting considerable ongoing support, even for
patients being managed by other teams. Those not
receiving haematology input at this time may have
had other acute comorbidities; we also noted that
some patients were not known to haematology, as
their disease was only formally diagnosed after death.
Continued management in haematology areas was
most common in patients with AML, perhaps because
of their significant dependency on supportive care.
Of the 240 patients dying in hospital, 7.5% were
managed at this time in dedicated palliative care areas,
either in major treating hospitals or smaller general
practitioner (GP)-led local hospital units. We found evi-
dence that palliative care clinicians were by far the most
likely to engage patients in discussions about end-of-life
preferences. This suggests a clear link between palliative
care input and advance care planning. It is possible,
however, that patients may have decided they wanted to
die at home and received palliative care input to facili-
tate this. The reason preferred place of death was dis-
cussed less often in care of the elderly areas is unclear.
We were not able to identify any other studies focusing
on haematological cancers, or using identical methods,
with which to directly compare our findings; many of
the existing studies were from different geographical
locations, and so were also not directly comparable.
Looking very generally, however, the proportion of
people we identified with a discussion about preferred
place of death falls within the broad range (18.7–87%)
reported in UK studies from palliative care settings.42–47
The proportion of patients preferring hospital death was
generally much higher in our study and much lower for
home death than that reported in other studies of
patients with cancer, where hospital death was often the
least favoured option.4 48 49 The proportion of people
we identified who died in their preferred place was
broadly comparable to other studies;4 45 47–49 and others
also reported that people taking part in discussions about
place of death are less likely to die in hospital.4 37 45
STRENGTHS AND WEAKNESSES
One of the strengths of the study is that it is embedded
within a well-established population-based patient
cohort (HMRN), which covers a large area that is repre-
sentative of the UK.24 25 We focused on two large treat-
ing hospitals within this area, which together diagnose
around a third of all HMRN patients. The existing
study infrastructure ensured that we were able to iden-
tify all those who were diagnosed with the diseases of
interest in these hospitals, and who died during the spe-
cified time-intervals. It is possible that awareness of the
study may have influenced the provision of healthcare
within the targeted hospitals, particularly advance care
planning and discussions of end-of-life preferences. The
study was, however, instigated towards the latter part of
the follow-up period and much of the data were
collected retrospectively, so we do not believe that
patient care was unduly influenced in this respect.
In terms of study generalisability, we have no reason
to believe that the preferences of patients included in
the study are likely to differ significantly from those
of the wider HMRN cohort. This is because clinical
practice across the area adheres to national guide-
lines.24 25 We do appreciate, however, that some area-
based variation, both regionally and nationally, is inev-
itable, probably driven by factors such as resource and
service availability. Variations in preferences and prac-
tices may also occur internationally, as a result of dif-
ferences in healthcare systems.
Our data collection techniques were thorough and we
are confident that the majority of documented evidence
about preferred place of death, and also the clinical spe-
cialties providing care, was identified in the data sources
examined. In common with other studies, we noted the
lack of a systematic approach to the recording of pre-
ferred place of death.46 It is possible, therefore, that dis-
cussions may have occurred that were not documented
and so not identified by researchers. Furthermore, we
did not examine certain primary care records (eg, GP,
district nurse) or hospice/nursing home records, which
may have contained additional information about pre-
ferred place of death. In this respect, the proportion of
patients we identified with a discussion about place of
death represents a minimum value.
We documented all stated preferences about place of
death, including changes over time and used the deci-
sion closest to death to analyse congruence between
preferred and actual place of death. It should be noted
that the preferences at this time therefore reflect the
choice made when the patient is becoming increasingly
ill and may already be in hospital. Furthermore,
although preferred place of care and preferred place of
death are recognised as different issues,50 our analysis
focused solely on place of death. This is because there
was not usually enough information in the medical
records to enable us to systematically differentiate
between these two concepts with any confidence.
IMPLICATIONS FOR PRACTICE AND FUTURE
RESEARCH
Earlier discussion about prognosis and potential com-
plications of treatment may promote advance care
planning among haematology patients. This could take
place around diagnosis for all patients, whether they
are being treated with curative, life-prolonging or pal-
liative intent. An inherent difficulty associated with
this, however, is balancing hope with uncertainty. The
patient and their family’s knowledge and acceptance of
the expected disease trajectory must be taken into con-
sideration, along with their willingness to engage in
discussions about end-of-life care and place of death at
a time when they may prefer to focus solely on cure.
More research is needed to fully understand the
reasons why place of death was not discussed, why
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patients did not die in their preferred place if this was
stated, and any changes that could be made to practice
to rectify such issues in future. If this is due to resources
issues improvements could be made via changes to the
commissioning and allocation of services; other reasons,
such as social circumstances and different carer prefer-
ences, may be harder to address. It would also be useful
to compare preferences of haematology patients with
those of patients with other cancers in the same geo-
graphical area. If haematology patients are more likely
than others to choose to remain in hospital at the end of
their lives, then it is essential that adequate care is avail-
able within this setting to meet these needs.
CONCLUSION
Our study has introduced evidence about preferred
and actual place of death in haematological malignan-
cies. We have shown that many patients with these
diseases do have the opportunity to discuss preferred
place of death, and do die in their preferred place.
However, we also identified that a substantial propor-
tion did not take part in such discussions, and that
hospital deaths were particularly common in this
group. Hence, there is scope to improve practice, par-
ticularly among those dying soon after diagnosis, and
those with the propensity to die suddenly and unex-
pectedly. Our findings highlight the complexity of
haematological cancers, demonstrated in the multidis-
ciplinary provision of care, and the sustained input
from the haematology team, in many cases continuing
until the last week of life. We found evidence that
some patients wanted to remain in hospital at the
time of their death, and the extent to which this com-
pares with that of patients with other cancers is of
interest.
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